The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the approval of Copiktra as monotherapy for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia after at least two prior therapies and follicular lymphoma that is refractory to at least two prior systemic therapies.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
